Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH001 in Advanced Solid Tumors
NCT04699929Phase 1Completed
- Sponsor
- Eucure Biopharma
- Start
- Jan 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YH001 in solid tumor (advanced stage), sponsored by Eucure Biopharma. Primary endpoints: Overall safety and tolerability profile of YH001 (adverse events) at 1 year, Maximum Tolerated Dose at 21 days and 1 more. Started Jan 2021; status: completed.
02
Drugs
YH001
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04699929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04699929.